capiton initiated a General Partner (GP)-led single-asset secondary transaction to provide its portfolio company, KD Pharma Group, with duration and follow-on capital to finance significant future growth.
Through a competitive bidding process, the transaction gave existing limited partners of capiton IV fund the option to sell their stake in KD Pharma Group or to stay invested in KD Pharma Group via a continuation fund. The transaction also gives new investors the opportunity to invest in a growing portfolio company. Pantheon and Aberdeen Standard Investments participated as principal new investors alongside other renowned institutions.
Duff & Phelps served as the financial advisor to capiton IV fund and provided a fairness opinion in connection with the transaction.
About capiton
capiton is an independent, owner-managed private equity firm that manages a total fund volume of EUR 1.0 billion. The investment portfolio of capiton AG currently comprises 11 medium-sized companies. As an equity partner, capiton supports management buy-outs and growth financing in established medium-sized companies.
About KD Pharma Group
KD Pharma Group is a worldwide leading omega-3 ingredients producer focused on highly purified omega-3 fatty acids for pharmaceutical and nutraceutical products. Since the acquisition by capiton IV fund in 2013, KD Pharma Group has grown from a single-digit revenue business to one of the industry’s largest players.
Bob Bartell, CFA
Vice Chairman and Managing Director
Chicago
